ALKERMES | ALKS - SCHULD





SCHULD Veränderung Datum
AbbVie USD 1000K 70.48B 2025-09
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
ALKERMES USD 71.6M 1.08M 2025-09
Amgen USD 54.59B 1.62B 2025-09
Biogen USD 6.29B 1.7M 2025-12
BioMarin Pharmaceutical USD 604.24M 375K 2025-09
Bristol-Myers Squibb USD 51.04B 112M 2025-09
Coherus Biosciences USD 294.92M 1.25M 2025-03
Eli Lilly USD 42.51B 2.6B 2025-09
Gilead Sciences USD 24.94B 5M 2025-09
Heron Therapeutics USD 149.65M 157K 2024-09
Ionis Pharmaceuticals USD 2.33B 1.1B 2025-12
J&J USD 45.8B 4.97B 2025-09
Malin Corporation EUR 100K 0 2023-12
Merck USD 41.37B 5.97B 2025-09
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 428.4M 10.7M 2025-09
Otsuka Holdings JPY 211.51B 41.2B 2025-06
Ovoca Bio EUR 0 0 2021-06
Pfizer USD 60.85B 78M 2025-09
Regeneron Pharmaceuticals USD 2.71B 400K 2025-09
Vertex Pharmaceuticals USD 1.83B 307.4M 2025-09